4.5 Article

Topical and oral bexarotene

Journal

DERMATOLOGIC THERAPY
Volume 26, Issue 5, Pages 400-403

Publisher

WILEY
DOI: 10.1111/dth.12087

Keywords

bexarotene; cutaneous T cell lymphoma; retinoids

Categories

Ask authors/readers for more resources

Bexarotene is a retinoid that specifically binds retinoid X receptors and has numerous effects on cellular growth and differentiation. It is approved for the treatment of cutaneous T cell lymphoma both topically and systemically. Adverse effects include hyperlipidemia, central hypothyroidism, and neutropenia with bexarotene capsules, and an irritant dermatitis with bexarotene gel. With aggressive management of these potential side effects, bexarotene is an additional option in the armamentarium for management of cutaneous T cell lymphoma.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available